The Drug Enforcement Agency today said it is increasing annual caps for controlled substances whose supplies are in high demand due the COVID-19 crisis. DEA said it will increase the 2020 Aggregate Production Quotas by 15% for certain substances needed for the treatment of COVID-19, including fentanyl, morphine, hydromorphone, codeine, ephedrine, pseudoephedrine, and certain controlled substance intermediates which are essential to their production. The agency also is increasing the authorized amounts of certain schedule III and IV controlled substances needed to treat patients on ventilators that may be imported into the United States, including ketamine, diazepam, midazolam, lorazepam, and phenobarbital.

DEA said it will reevaluate demand and adjust APQ levels as needed after the health emergency recedes.

In a letter sent April 1, the AHA, American Medical Association, American Society of Anesthesiologists, American Society of Health-System Pharmacists, and Association for Clinical Oncology urged DEA to allow drug manufacturers and 503B outsourcing facilities to receive increased APQ controlled-substance allocations during the COVID-19 crisis.

Related News Articles

Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…